dipyridamole has been researched along with Sarcoma 180 in 4 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Sarcoma 180: An experimental sarcoma of mice.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combined effect of methotrexate (MTX) with dipyridamole, an inhibitor of nucleoside transport, was studied in ascitic Sarcoma 180 cells." | 7.67 | Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells. ( Bover, L; Cabral, S; Leis, S; Mordoh, J; Nembrot, M, 1984) |
| "The combined effect of methotrexate (MTX) with dipyridamole, an inhibitor of nucleoside transport, was studied in ascitic Sarcoma 180 cells." | 3.67 | Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells. ( Bover, L; Cabral, S; Leis, S; Mordoh, J; Nembrot, M, 1984) |
| " In combination with amphotericin B (AmB), DP enhanced the inhibitory effect of MTX on sarcoma 180 in mice without a significant increase in toxicity." | 3.67 | [Potentiated antitumor effect of methotrexate by dipyridamole]. ( Cao, SS, 1989) |
| " This study provided evidence that the combination of DP and amphotericin B (AmB) significantly potentiated the inhibitory effect of 5-fluorouracil (FU) or methotrexate (MTX) against a panel of transplantable tumors including sarcoma 180, cervical carcinoma U14, and Lewis lung carcinoma in mice." | 3.67 | Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. ( Cao, SS; Zhen, YS, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cabral, S | 1 |
| Leis, S | 1 |
| Bover, L | 1 |
| Nembrot, M | 1 |
| Mordoh, J | 1 |
| Cao, SS | 2 |
| Zhen, YS | 1 |
| Kusumoto, H | 1 |
| Maehara, Y | 1 |
| Anai, H | 1 |
| Kusumoto, T | 1 |
| Sugimachi, K | 1 |
4 other studies available for dipyridamole and Sarcoma 180
| Article | Year |
|---|---|
Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells.
Topics: Animals; Biological Transport; Deoxycytidine; Deoxyuridine; Dipyridamole; DNA Replication; Drug Anta | 1984 |
[Potentiated antitumor effect of methotrexate by dipyridamole].
Topics: Amphotericin B; Animals; Antineoplastic Agents; Biological Transport; Dipyridamole; Drug Synergism; | 1989 |
Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B.
Topics: Amphotericin B; Animals; Antimetabolites, Antineoplastic; Dipyridamole; Drug Evaluation, Preclinical | 1989 |
Potentiation of adriamycin cytotoxicity by dipyridamole against HeLa cells in vitro and sarcoma 180 cells in vivo.
Topics: Animals; Cell Survival; Dipyridamole; Doxorubicin; Drug Synergism; HeLa Cells; Humans; Mice; Sarcoma | 1988 |